11th Nov 2020 - Global Angina Pectoris Drugs Market is estimated to reach USD 10.6 billion by 2022 owing to the rising number of patients suffering from angina pectoris and the probable acceptance of modern therapies like varespladib and Generx that are in late stage of clinical development. If these modern therapies are approved, they are expected to contribute impressively to the growth of angina pectoris drugs industry since they will be sold at premium prices by manufacturing companies.
When chest pain (angina) occurs, physicians suggest blockages in heart arteries. There are many types of angina one may have, but the major ones are chronic stable angina that occurs when the heart is working steadily and the unstable angina which occurs when the chest pain gets worse. The other types comprise variant angina and microvascular angina. At present, angina pectoris treatments are not comparatively effective and therefore newbies are experiencing new opportunities to introduce more effective therapies and contribute the growth of angina pectoris drugs market.
Access Angina Pectoris Drugs Market Report with TOC @ https://www.millioninsights.com/industry-reports/angina-pectoris-drugs-market
The rise in chronic diseases is one of the major growth factors for the growth of angina pectoris drugs industry. Angina Pectoris is mainly caused by growing prevalence of chronic diseases like high blood pressure, diabetes and obesity. High blood pressure and diabetes are likely to develop more serious health issues associated with numerous important organs. Obesity is the main reason for fatal cardiac disorders irrespective of the person is suffering from high blood pressure or diabetes. The increasing geriatric population is also projected to encourage the demand for angina pectoris drugs in the forecast period.
(β-blockers) β-Adrenoceptor antagonists are suggested for the first line treatment of heart failure, arterial fibrillation, coronary artery disease and hypertension with heart failure, angina pectoris, or prior myocardial infarction. β-Blocker therapy is also used in asymptomatic patients with large areas of ischemia (level IIa C evidence) and in microvascular angina to recover effort-related angina symptoms. A research revealed that chronic stable angina affects very less population in the western countries with an anticipated yearly risk of death and non-fatal myocardial infraction of comparatively less population.
Angina pectoris drugs market is categorized on the basis of drug class, end-users, and geography. On the basis of drug class, the market is divided into Angiotensin-converting enzyme inhibitors, Beta-adrenergic blocking agents, Calcium channel blockers, Short & Long – acting Nitroglycerines, Anti-ischemic agents and Antiplatelet agents. In terms of end-users, angina pectoris drugs industry is segmented as retail pharmacies, hospital pharmacies and online pharmacies.
The prominent players in angina pectoris drugs industry comprise Astellas Pharma, AstraZeneca PLC, Ark Therapeutics Group plc, Cardium Therapeutics, Cardeus Pharmaceuticals, CardioVascularBioTherapeutics (CVBT), HUYA Bioscience International LLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Korea Otsuka Pharmaceutical Co.Ltd, Pfizer, Inc., Baxalta US Inc., Gilead Sciences, Inc, Sanofi SA, and TSH Biopharm Corporation Limited.
Request a Sample Copy of Angina Pectoris Drugs Market Report @ https://www.millioninsights.com/industry-reports/angina-pectoris-drugs-market/request-sample
Regional Outlook (% market share; 2016 - 2022)
- U.S.
- U.K.
- France
- Germany
- Italy
- Spain
- Japan
Visit Our Blog: https://marketreportsassistance.wordpress.com
Get in touch
At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.
Contact Person:
Ryan Manuel
Research Support Specialist, USA
Email: [email protected]
Million Insights
Office No. 302, 3rd Floor, Manikchand Galleria,
Model Colony, Shivaji Nagar, Pune, MH, 411016 India
Phone: 91-20-65300184
Email: [email protected]
Angina Pectoris is mainly caused by growing prevalence of chronic diseases like high blood pressure, diabetes and obesity.
High blood pressure and diabetes are likely to develop more serious health issues associated with numerous important organs.
The increasing geriatric population is also projected to encourage the demand for angina pectoris drugs in the forecast period.
β-Blocker therapy is also used in asymptomatic patients with large areas of ischemia (level IIa C evidence) and in microvascular angina to recover effort-related angina symptoms.
A research revealed that chronic stable angina affects very less population in the western countries with an anticipated yearly risk of death and non-fatal myocardial infraction of comparatively less population.Request a Free Sample Copy of Angina Pectoris Drugs Market Report @ https://www.millioninsights.com/industry-reports/angina-pectoris-drugs-market/request-sampleGlobal Angina Pectoris Drugs Market is estimated to reach USD 10.6 billion by 2022 owing to the rising number of patients suffering from angina pectoris and the probable acceptance of modern therapies like varespladib and Generx that are in late stage of clinical development.
If these modern therapies are approved, they are expected to contribute impressively to the growth of angina pectoris drugs industry since they will be sold at premium prices by manufacturing companies.When chest pain (angina) occurs, physicians suggest blockages in heart arteries.
Global Angina Pectoris Drugs Market is estimated to reach USD 10.6 billion by 2022 owing to the rising number of patients suffering from angina pectoris and the probable acceptance of modern therapies like varespladib and Generx that are in late stage of clinical development.
If these modern therapies are approved, they are expected to contribute impressively to the growth of angina pectoris drugs industry since they will be sold at premium prices by manufacturing companies.
Angina Pectoris is mainly caused by growing prevalence of chronic diseases like high blood pressure, diabetes and obesity.
β-Blocker therapy is also used in asymptomatic patients with large areas of ischemia (level IIa C evidence) and in microvascular angina to recover effort-related angina symptoms.
A research revealed that chronic stable angina affects very less population in the western countries with an anticipated yearly risk of death and non-fatal myocardial infraction of comparatively less population.
The prominent players in angina pectoris drugs industry comprise Astellas Pharma, AstraZeneca PLC, Ark Therapeutics Group plc, Cardium Therapeutics, Cardeus Pharmaceuticals, CardioVascularBioTherapeutics (CVBT), HUYA Bioscience International LLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Korea Otsuka Pharmaceutical Co.Ltd, Pfizer, Inc., Baxalta US Inc., Gilead Sciences, Inc, Sanofi SA, and TSH Biopharm Corporation Limited.
11 February 2020 - Global Human Growth Hormone (HGH) Market is anticipated to witness an exponential growth in the forecast period.
Human growth hormone is mainly responsible for regeneration and growth among humans and stimulates cell reproduction.
Factors such as presence of a large pool of patients, technological advancements, demand for better-quality and cost-effective human growth hormones, increasing compliance for human growth hormone drugs and massive unexplored markets in the developing economies, such as China and India.Furthermore, advanced research and development services, and new drug developments by the key companies, increasing occurrences of human growth hormone deficiency diseases, and growing aged population are likely to propel the human growth hormone industry in the forthcoming period.
Human growth hormone (HGH) industry is anticipated to expand at a CAGR of 7.5% in the upcoming period as the scope, product types, and its applications are increasing across the globe.Human growth hormone market could be explored by route administration, application, distribution channel, and geography.
It is likely to witness substantial growth in the years to come.
The key factors that could be attributed to the growth of the market include the preference for the subcutaneous technique is rising as it leads to the important growth in development rates and low occurrence of antibody progress.
Global Human Growth Hormone (HGH) Market is anticipated to witness an exponential growth in the forecast period.
Human growth hormone is mainly responsible for regeneration and growth among humans and stimulates cell reproduction.
Factors such as presence of a large pool of patients, technological advancements, demand for better-quality and cost-effective human growth hormones, increasing compliance for human growth hormone drugs and massive unexplored markets in the developing economies, such as China and India.Furthermore, advanced research and development services, and new drug developments by the key companies, increasing occurrences of human growth hormone deficiency diseases, and growing aged population are likely to propel the human growth hormone industry in the forthcoming period.
On the other hand, the high cost of treatment, strict governing approvals, and adverse effects associated with the usage of synthetic human growth hormones are anticipated to hinder human growth hormone drugs market growth in future.Access Sample Report of this report @ https://www.millioninsights.com/industry-reports/human-growth-hormone-drugs-market/request-sampleHowever, increasing acceptance of growth hormone drugs, as anti-aging drug and the rising popularity of human growth hormone drugs is likely to create lucrative opportunities for the market.
Human growth hormone (HGH) industry is anticipated to expand at a CAGR of 7.5% in the upcoming period as the scope, product types, and its applications are increasing across the globe.Human growth hormone market could be explored by route administration, application, distribution channel, and geography.
It is likely to witness substantial growth in the years to come.
Global Human Growth Hormone (HGH) Market is anticipated to witness an exponential growth in the forecast period.
Human growth hormone is mainly responsible for regeneration and growth among humans and stimulates cell reproduction.
Factors such as presence of a large pool of patients, technological advancements, demand for better-quality and cost-effective human growth hormones, increasing compliance for human growth hormone drugs and massive unexplored markets in the developing economies, such as China and India.Furthermore, advanced research and development services, and new drug developments by the key companies, increasing occurrences of human growth hormone deficiency diseases, and growing aged population are likely to propel the human growth hormone industry in the forthcoming period.
On the other hand, the high cost of treatment, strict governing approvals, and adverse effects associated with the usage of synthetic human growth hormones are anticipated to hinder human growth hormone drugs market growth in future.However, increasing acceptance of growth hormone drugs, as anti-aging drug and the rising popularity of human growth hormone drugs is likely to create lucrative opportunities for the market.
Human growth hormone (HGH) industry is anticipated to expand at a CAGR of 7.5% in the upcoming period as the scope, product types, and its applications are increasing across the globe.Request Sample Copy of This Market Research @ https://www.millioninsights.com/industry-reports/human-growth-hormone-drugs-market/request-sample Human growth hormone market could be explored by route administration, application, distribution channel, and geography.
It is likely to witness substantial growth in the years to come.
Market Analysis and Insight: Europe Anticoagulation Therapy MarketEurope Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) – Industry Trends and Forecast to 2026Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open.
Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi.
There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).Europe anticoagulation therapy market is projected to register a substantial CAGR in the forecast period of 2019 to 2026.Get a Sample Copy of report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-anticoagulation-therapy-marketSegmentation: Europe Anticoagulation Therapy MarketEurope anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and othersOn the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and othersOn the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and othersOn the basis of route of administration, the market is segmented into oral and injectableOn the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and othersOn the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacementOn the basis of type, the market is segmented into generics and brandedOn the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and othersOn the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacyCompetitive Analysis: Europe Anticoagulation Therapy MarketSome of the major players operating in the Europe anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical（Group）Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.Get Detailed Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=europe-anticoagulation-therapy-marketRecent DevelopmentsIn September 2018, Sanofi announced Health got Canada approval for Lovenox’s (enoxaparin sodium) new indication toprevent thrombus formation in the extra-corporeal circulation during haemodialysis in patients who are having end stage kidney disease (ESKD).
This will attract the potential consumers helping in the growth of the company.In August 2018, Bayer AG received the European Commission (EC) approval for Xarelto (rivaroxaban) 2.5 mg.
It is indicated for reduction of chances of cardiovascular situations such as stroke/ heart attack in patients with chronic coronary artery disease (CAD), cardiovascular (CV) death, and peripheral artery disease (PAD).
This approval will help the company to develop anticoagulant business in European countries.In June 2015, Daiichi Sankyo Company, Limited received the EU approval for LIXIANA (edoxaban).
